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Abstract
 
HLA-B
 
*
 
4402 and B
 
*
 
4403 are naturally occurring MHC class I alleles that are both found at a
high frequency in all human populations, and yet they only differ by one residue on the 
 
 
 
2 helix
 
(B
 
*
 
4402 Asp156
 
→
 
B
 
*
 
4403 Leu156). CTLs discriminate between HLA-B
 
*
 
4402 and B
 
*
 
4403,
and these allotypes stimulate strong mutual allogeneic responses reflecting their known barrier
to hemopoeitic stem cell transplantation. Although HLA-B
 
*
 
4402 and B
 
*
 
4403 share 
 
 
 
95% of
their peptide repertoire, B
 
*
 
4403 presents more unique peptides than B
 
*
 
4402, consistent with
the stronger T cell alloreactivity observed toward B
 
*
 
4403 compared with B
 
*
 
4402. Crystal
structures of B
 
*
 
4402 and B
 
*
 
4403 show how the polymorphism at position 156 is completely
buried and yet alters both the peptide and the heavy chain conformation, relaxing ligand selection
by B
 
*
 
4403 compared with B
 
*
 
4402. Thus, the polymorphism between HLA-B
 
*
 
4402 and
B
 
*
 
4403 modifies both peptide repertoire and T cell recognition, and is reflected in the para-
doxically powerful alloreactivity that occurs across this “minimal” mismatch. The findings suggest
that these closely related class I genes are maintained in diverse human populations through
their differential impact on the selection of peptide ligands and the T cell repertoire.
Key words: class I histocompatibility molecules • antigen presentation • crystallography • 
X-ray diffraction • graft rejection • polymorphism
protective immunity against microbes (1–3). HLA alleles
can differ from each other by only a single amino acid
(“micropolymorphism”) or by 
 
 
 
30 amino acids (4). It has
been suggested that there are nine major HLA class I “super-
types,” or clusters of alleles, that each possess a unique
broad specificity for common anchor motifs in antigenic
peptides (5). Alleles from each of these supertypic families
are distributed in virtually all human populations and account
 
W.A. Macdonald and A.W. Purcell contributed equally to this work.
The online version of this article includes supplemental material.
 
Address correspondence to James McCluskey, Dept. of Microbiology
and Immunology, The University of Melbourne, Parkville, Victoria
3010, Australia. Phone: 613-8344-5709; Fax: 613-9347-3226; email:
jamesm1@unimelb.edu.au; or Jamie Rossjohn, The Protein Crystallogra-
phy Unit, Dept. of Biochemistry and Molecular Biology, School of Bio-
medical Sciences, Monash University, Clayton, Victoria 3168, Australia.
Phone: 613-9905-3736; Fax: 613-9905-4699; 
email: Jamie.Rossjohn@med.monash.edu.au
 
Abbreviations used in this paper:
 
 H-bond, hydrogen bond; MALDI-TOF,
matrix-assisted laser desorption/ionization time-of-flight; MS, mass spec-
trometry; RP, reverse phase; v.d.w., van der Waals.
 
Introduction
 
HLA class I molecules are characterized by a high level of
polymorphism presumed to reflect natural selection forT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
680
 
Impact of a Naturally Selected Polymorphism on HLA Class I
 
for the majority HLA-A and -B polymorphism, suggesting
that their maintenance reflects an adaptable strategy for in-
duction of immunity toward diverse microbial ligands.
The widespread distribution of many low frequency
HLA polymorphisms is probably an artifact of human mi-
gration and admixture of population groups that originally
possessed a limited degree of HLA polymorphism (2). This
might explain why most human populations often have
only one or two alleles from each of the different HLA class
I supertypes (5), such that a complete picture of HLA diver-
sity is only appreciated when multiple racial groups are ex-
amined. An exception to this notion is the HLA-B44 family
of alleles, in which both B
 
*
 
4402 and B
 
*
 
4403 are present in
most human populations at combined phenotypic frequen-
cies of up to 40% (6). HLA-B
 
*
 
4402 and B
 
*
 
4403 are the two
most common members of the HLA-B44 supertype and
participate in antiviral (7–10), antitumor (11–13), and minor
Ag-specific responses (14, 15). HLA-B
 
*
 
4402 (Asp156) and
B
 
*
 
4403 (Leu156) differ by only a single amino acid located
on the 
 
 
 
2 helix, essentially constituting a dimorphism
within the HLA-B44 family because the other HLA-B44
alleles are much less common (generally, gene frequency
 
 
 
0.01; reference 6). These two B44 allotypes are also asso-
ciated with different ancestral MHC haplotypes, suggesting
an ancient origin for this di-allelism (16, 17).
Members of the B44 supertype share a preference for
peptides with negatively charged residues at P2 (Glu) and
hydrophobic residues at the COOH terminus (18, 19).
Previous comparisons of ligands eluted from B
 
*
 
4402 and
B
 
*
 
4403 molecules have not revealed any difference in their
peptide repertoire, raising the question of what functional
differences between these alleles support their high preva-
lence in all human populations.
Despite the similarity of their peptide repertoires, mis-
matching of B
 
*
 
4402 and B
 
*
 
4403 in hemopoeitic stem cell
transplantation has been associated with transplant rejection
(19, 20) and acute graft versus host disease (21), indicating
that they represent a significant barrier to clinical transplan-
tation. Moreover, CTL can discriminate between B
 
*
 
4402
and B
 
*
 
4403 allotypes, indicating structural differences that
are highly relevant to T cells (22–24). The similarity in
peptide repertoires of B
 
*
 
4402 and B
 
*
 
4403 suggests that the
strong alloresponses between these alleles do not reflect
presentation of different peptides (18, 19), but may reflect
the accessibility of the 
 
 
 
2 domain residue 156 for direct in-
teraction with the TcR (24). Moreover, analyses of HLA-
A2 mutants have confirmed the strong influence of posi-
tion 156 on T cell recognition (25) and suggest a limited
influence for this residue on peptide binding (26). On the
other hand, residue 156 has also been predicted to influ-
 
Table I.
 
Sequences of Individually Sequenced Peptides
 
Peptide sequence Source Mass Frac. B
 
*
 
4402 B
 
*
 
4403
 
Shared ligands Daltons
 
EEFGRAFSF HLA DPA
 
*
 
0201 1,088.5 34
 
         
 
AEDKENYKKF Hsp90
 
 
 
 (428-437) 1,270.6 33
 
     
 
AEMGKGSFKY Translation elongation 
factor 1
 
 
 
 (47-56)
1,116.5 27
 
     
 
EEYNGGLVTV Ig heavy chain (106-115) 1,079.6 31
 
      
 
FEQIIERF Human EST 1,080.5 31
 
     
 
EEPTVIKKY Human EST 1,105.6 28
 
     
 
DEVGIVTKY Unknown 1,152.6 28
 
     
 
EEVDLSKDIQHW Ribonucleoside diphosphate
reductase M2 chain
1,497.7 32
 
     
 
Ligands preferentially
bound to B
 
*
 
4403
 
AETPDIKLF Ribosomal protein s5 1,032.5 33
 
     
 
KEIKDILIQY Ribosomal protein s12 1,261.7 32
 
     
 
AEVDKVTGRF Ribosomal protein s21 1,120.6 26
 
     
 
NELNIIHKF Human EST 1,126.6 32
 
    
 
Ligands preferentially
bound to B
 
*
 
4402
 
EEVHDLERKY Human EST 1,316.6 24
 
     
 
YEGLLDYW Ig heavy chain (86-93) 1,057.6 31
 
     T
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ence the D/E pockets (24) that interact with the central
core of the bound peptide (P4-P7; reference 27).
To help resolve these issues, we have evaluated the
structural and functional properties of HLA-B
 
*
 
4402 and
B
 
*
 
4403.
 
Materials and Methods
 
Cell Lines and Culture.
 
The B-lymphoblastoid cell line
Hmy2.C1R (28) is class I–deficient, having no detectable HLA-
A, very low levels of HLA-B35, normal HLA-Cw4, and intact
antigen processing and presentation pathways (29). Transfection
of HLA-B
 
*
 
4402 and B
 
*
 
4403 into C1R (C1R.B
 
*
 
4402 and
C1R.B
 
*
 
4403, respectively) and cell culture conditions have been
described previously (29). LC-13 and DD1 CTL clones were
maintained in RPMI 1640 with supplements and restimulated ev-
ery 10–14 d in the presence of recombinant IL-2 and HLA-
matched lymphoblastoid cell lines or PBMCs pulsed with the ap-
propriate peptide antigen. Derivation of CD8
 
 
 
 CTL clone
5101.1999.23 has been described previously (30).
 
Allogeneic MLR and Intracellular Cytokine Staining. 
 
MLRs
were performed using PBMCs from healthy blood donors (
 
n 
 
 
 
13) matched for HLA-A, -B, and sometimes -C, but mismatched
for HLA-B
 
*
 
4402 and B
 
*
 
4403 (and HLA class II). The HLA class
I typing was as follows: B
 
*
 
4402 group (
 
n
 
 
 
 
 
 10: A
 
*
 
02011/9,
03011; B
 
*
 
44021, 5701; and C
 
*
 
0501/02/03, 0602/03/07) and
B
 
*4403 group (n   3: A*02011/9, 3011; B*44031, 5701; and
C*0602/03/07, 1601).
In brief, 107 responder and 5   106 irradiated (3,000 rad) stim-
ulator cells were cultured in RPMI 1640 plus 10% fetal calf se-
rum, supplemented with 10 U/ml of recombinant IL-2 (Cetus
Corporation) for 13 d at 37 C. On day 13, 2   105 responder T
cells were harvested and restimulated with a panel of APCs
(C1R, C1R.B*4402, and C1R.B*4403) at a cell concentration of
105 for 2 h at 37 C, 5% CO2. 10  g/ml brefeldin was added for
an additional 4 h, and responder T cells were stained with anti-
CD4 PE (clone SK3; Becton Dickinson) and anti-CD8 CyChrome
(BD Biosciences). Cells were fixed with 1% paraformadehyde
(ProSciTech), permeabilized with 0.3% saponin (Sigma-Aldrich),
and intracellular IFN-  was detected with an anti–IFN-  mAb
(clone 25723.11; Becton Dickinson). The percentage of CD8  T
cells producing IFN-  was determined by flow cytometry using
FlowJo software (Tree Star Inc.).
Purification of Cell Surface–Associated HLA–B44 Complexes and
Peptide Analysis. Purification of HLA-B*4402 and B*4403 was
performed from 5   109 C1R.B*4402 and C1R.B*4403 cells
grown in roller bottles as described previously (31). Peptides were
recovered as described previously (31). Peptides were separated
by reverse phase (RP)-HPLC using a SMART system HPLC
(Amersham Biosciences) with a  RPC C2 /C18 column (2.1
mm [inside diameter]   10 cm). Eluted peptides were resolved
from contaminating detergent polymers by using a rapid gradient
from 0 to 60% acetonitrile in 0.1% aqueous TFA (12% increase
in buffer B (organic)/min, 200  l/min). This material was sub-
jected to pool Edman sequencing and matrix-assisted laser de-
sorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS).
MS. MALDI-TOF MS was performed using a Reflex mass
spectrometer (Bruker) as described previously (31). Care was
taken to ensure reproducibility of MS results on HPLC fractions
(Figs. S1–S3 available at http://www.jem.org/cgi/content/full/
jem.20030066/DC1). Peptide sequencing by Q-TOF electro-
spray ionization MS was performed as described previously (31,
32) on a Q-STAR pulsar-i Q-TOF MS (Applied Biosystems).
Putative peptide sequences were obtained by database compari-
Table II. Data Collection and Refinement Statistics
Units B*4402 B*4403
Data collection statistics
Temperature K 100 100
Space group P212121 P212121
Cell dimensions (a, b, c) Å 50.81, 81.78, 
110.07
50.72, 82.30,
109.55
Resolution Å 1.6 1.7
Total No. observations 282,153 176,666
No. unique observations 59,302 50,615
Multiplicity 4.8 3.5
Data completeness % 96.8 (92.7) 96.7 (93.5)
No. data  2 1 85.2 80.9
I/ 1 9.4 (2.0) 18.8 (3.2)
Rmerge
a % 4.9 (27.6) 5.6 (54.1)
Refinement statistics
Non–hydrogen atom
Protein 3,162 3,162
Water 659 481
Acetate 2
Resolution Å 50-1.6 50-1.7
Rfactor
b % 21.4 22.9
Rfree % 23.4 26.2
rms deviations from ideal
Bond lengths Å 0.005 0.006
Bond angles   1.27 1.26
Dihedrals   24.92 25.08
Impropers   0.74 0.72
Ramachandran plot
Most favored 92.0 91.4
And allowed region % 7.4 8.0
B-factors
Average main chain Å2 20.3 25.1
Average side chain Å2 22.9 28.1
Average water molecule Å2 36.3 40.5
rms deviation bonded Bs 1.6 1.8
The values in parentheses are for the highest resolution bin (approximate
interval 0.1 Å). Two residues (Asp 29, Arg 239) that lie within
generously allowed regions of the Ramachandran plot, fit the electron
density very well. There are no residues in the disallowed region of the
Ramachandran plot.
aRmerge     Ihkl   <Ihkl>     Ihkl
bRfactor    Ihkl   Fo     Fc      Ihkl Fo  for all data except for 3%, which
was used for the Rfree calculation. Two residues (Asp29, Arg239),
which lie within generously allowed regions of the Ramachandran
plot, fit the electron density very well. There are no residues in the dis-
allowed region of the Ramachandran plot.T
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son of the fragmentation spectra using the MASCOT algorithm
(33) followed by manual assignment of expected fragments from
the highest score sequences (Table I).
Crystallization, Data Collection, and Structure Determination.
Recombinant B44 complexes were prepared from Escherichia coli,
refolded, and crystallized as described previously (34). The data
were processed and scaled using the HKL package (35) and
D*TREK (36), Table II. The HLA-B*4402 structure was solved
first using the molecular replacement method, using programs
from CCP4 suite (37). The progress of refinement was monitored
by the Rfree value (3% of the data) with neither a sigma, nor a low
resolution cut off being applied to the data. The structure was re-
fined using rigid-body fitting followed by the simulated-anneal-
ing protocol implemented in CNS (version 1.0; reference 38) and
interspersed with rounds of model building using the program
“O” (39). Water molecules were included in the model using
standard criteria. The subsequent HLA-B*4403 structure was
solved using the fully refined HLA-B*4402 structure, minus the
bound peptide, water molecules, and site of polymorphism mu-
tated to alanine. The refinement protocol implemented was iden-
tical to that of the HLA-B*4402 structure. For the HLA-B*4403
structure, two acetate ions were clearly visible in the electron
density map. The quality of the electron density and the stereo-
chemistry for the two fully refined, high resolution HLA-B44 al-
leles is excellent. The electron density for the bound peptide, as
well as the interacting residues, is unambiguous. A summary of
the refinement statistics is given in Table II. The coordinates have
been deposited in the Protein Data Bank (http://www.rcsb.org/
pdb), accession codes 1M60 (B*4402) and 1N2R (B*4403).
Online Supplemental Material. The general issue of reproduc-
ibility and quantitation of the mass spectra are addressed in Figs.
S1–S3. Fig. S1 shows the results of an experiment analyzing frac-
tions from two independent elution experiments; Fig. S2 shows
how the different peak heights in the mass spectra were compared
by using natural internal reference standards; and Fig. S3 shows
the results obtained when comparing the same samples but using
different types of mass spectroscopy technology (MALDI-TOF
versus ESI-QqTOF). Table S1 provides a detailed list of MHC-
peptide contacts for the crystal structures of B*4402 and B*4403.
Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20030066/DC1.
Results
T Cell Discrimination between HLA-B*4402 and B*4403.
Despite only a single amino acid difference in the primary
structure of HLA-B*4402 (156Asp) and B*4403 (156Leu),
previous papers have shown that CD8  T cells can readily
distinguish between these two molecules (22, 40, 41). For
example, allospecific CD8  CTL clones, LC13 and DD1
(42), kill C1R transfectants expressing HLA-B*4402 and
B*4405 but not transfectants expressing HLA-B*4403 (Fig.
1, A and B). On the other hand, an allospecific, anti-B*4402
CTL clone (30, 43) makes IFN-  in response to C1R-trans-
fectants expressing HLA-B*4402, B*4403, and B*4407 but
not B*4405 (Fig. 1 C). Accordingly, allogeneic T cell reac-
tivity can be used to probe structural differences in MHC al-
lotypes that may influence thymic selection (44) and periph-
eral diversity of T cells in immunity (3).
Therefore, we evaluated the in vitro alloresponse be-
tween individuals mismatched for B*4402 and B*4403, but
matched at both HLA-A loci and for the HLA-B trans al-
Figure 1. Differential T cell
recognition of HLA-B*4402 and
HLA-B*4403 by CD8  T cells.
CTL clones, LC13 (A), and
DD1 (B) lyse HLA-B*4402 but
not HLA-B*4403 targets; un-
transfected C1R (closed trian-
gles); and C1R-transfected APCs
expressing either B*4402 (open
squares), B*4403 (closed circles),
B*4405 (closed squares), or
B*4407 (closed triangles). (C) The
CTL clone 5101.1999.23 is al-
loreactive with HLA-B*4402
and HLA-B*4403. IFN-  pro-
duction was assayed after 4 h.
APCs: HERLUFF,  B*4403   
LCL; PITOUT, B*4402   LCL;
and auto HSV-2, autologous
cells infected with HSV-2. (D)
PBMCs from donors mis-
matched for B*4402 and B*4403
were cocultured in a 13-d MLR
supplemented with IL-2. The
specificity of the responding cells
was evaluated by restimulation
for 6 h with defined APCs. Ver-
tical axis, IFN-  staining; hori-
zontal axis, CD8 staining. Gates
are shown for IFN- –producing
CD8  T cells. The percentage of
positive cells is shown in each histogram. (E) The percentage of allospecific CD8  T cells was assayed as in Fig. 4 D for 28 independent MLR reactions
between B*4403 responders and B*4402 stimulators and 13 independent MLR reactions between B*4402 responders and B*4403 stimulators.T
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lele. After reciprocal allogeneic MLRs, CD8  T lympho-
cytes were restimulated with defined APCs to determine
their specificity, and T cells making IFN-  were enumer-
ated. Less than 1% of CD8  T cells responded after the al-
logeneic MLR when either syngeneic PBMCs or untrans-
fected C1R cells were used as APCs (Fig. 1 D, left).
However,  20% of CD8  T cells from B*4402  respond-
ers were activated by C1R.B*4403 APCs (Fig. 1 D, bot-
tom). Similarly, restimulation of B*4403  responders with
C1R.B*4402 APCs provoked IFN-  production in  10%
of CD8  T cells (Fig. 1 D, top).
The median percentage of alloreactive CD8  T cells in
the B*4402 anti-B*4403 vector was 11.3% (n   28; inde-
pendent donor pairs) compared with a median of 2%
B*4403 anti-B*4402 CD8  T cells (n   13; independent
donor pairs). Hence, there were nearly sixfold more respond-
ing T cells identified in MLRs from B*4402 anti-B*4403
mismatches than vice versa, indicating an asymmetry in the
magnitude of the alloresponse stimulated between these
two HLA allotypes in vitro (Fig. 1 E). These findings indi-
cate that the single residue that distinguishes B*4402 from
B*4403 has a profound effect on T cell recognition of these
alloantigens, which is likely to result in differential T cell
repertoire selection by these allotypes.
Isolation of HLA-B44–bound Peptides and Analysis of
Ligand Specificity. Differential T cell recognition of
B*4402 and B*4403 could result from differences in either
peptide repertoire or HLA heavy chain conformation (45,
46). Alternatively, identical peptide repertoires could be
presented in an altered manner due to structural changes at
the interface between the peptide loaded class I molecule
and the TcR (47, 48). Therefore, peptide repertoires of
HLA-B*4402 and B*4403 were examined using pool Ed-
man sequencing and high-resolution MALDI-TOF MS.
Apart from the previously reported P2Glu and P Tyr/Phe
anchor residues (12, 18, 19), minor differences were noted
between subdominant anchor residues with more pro-
nounced yields of valine at P3 for B*4403 and tryptophan
at P9 for B*4402 (Fig. 2).
When peptide pools were examined by MALDI-TOF
MS, a high degree of overlap was detected in the ligands
from HLA-B*4402 and B*4403 (Fig. 2), consistent with
previous work (12, 18, 19). Each peptide pool exhibited a
complex ionization pattern, with a common prominent
signal at (M   H)    1089.6, subsequently shown to be
self-peptide derived from HLA DP 46–54 (34). Differences
in ligand repertoire were evident between HLA-B*4402
and B*4403, such as the species of m/z 1033.6, 1121.5, and
1145.6 that were all more prevalent in HLA-B*4403 rela-
tive to B*4402.
Additional fractionation of the total eluates was per-
formed using a second dimension of RP-HPLC followed
by MALDI-TOF MS of each fraction. Fig. 3 A shows the
complexity of ligands identified in B*4402 as a function of
RP-HPLC retention time (right) and mass spectra (left).
The individual species identified in  60 RP-HPLC frac-
tions exhibited  95% overlap between HLA-B*4402 and
B*4403 (Fig. 3, B–G and unpublished data). Fig. 3 B shows
the mass spectra of fraction “B” (Fig. 3 A, right), derived
from HLA-B*4402 (MALDI-TOF, positive polarity), and
HLA-B*4403 (negative polarity). Here, the species at m/z
1121.3 appears to be specific to the HLA-B*4403 eluate
and was not detected in neighboring fractions from either
HLA-B*4402 or B*4403. This peptide was identified as
amino acids 37–46 of human ribosomal protein S21, a nat-
ural ligand of HLA-B*4403 (Table I; reference 18). On the
other hand, the species of mass 1180.4 was preferentially
recovered from B*4402 eluates. Fractions “C” and “F”
(Fig. 3 A, right) revealed greater complexity of peptides
bound to HLA-B*4403 versus B*4402 (Fig. 3, C and F),
whereas spectra of equal complexity but distinct composi-
tion were observed in other fractions (Fig. 3, D and E).
Some fractions contained ligands that were mostly identical
in B*4402 and B*4403 (Fig. 3 G).
Approximately 5% of all ligands were either preferen-
tially presented by B*4403 or B*4402, or were uniquely re-
covered from one or other allotype. A systematic examina-
tion of all fractions identified 116 such peptides, of which
80% were “biased” toward presentation by the B*4403
molecule. Only 20% of the biased ligands were preferen-
tially presented by B*4402. This bias was even more
marked ( 90% B*4403) when the analysis was confined to
Figure 2. Subtle differences in ligand selection by B*4402 and B*4403
despite a shared dominant anchor motif and overlapping peptide repertoires.
Pool Edman sequence analysis of peptides eluted from HLA-B*4402 and
B*4403. Comparison of B*4402 and B*4403 peptide repertoires by
MALDI-TOF MS. Total peptide eluates from HLA-B*4402 (positive po-
larity spectra) and HLA-B*4403 (negative polarity spectra) after a single-
dimension chromatographic separation.T
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ligands with the strongest ionization signals. Sequencing of
shared or unique peptides associated with HLA-B*4402
and B*4403 verified the observations made by MS (Table
I). Tryptophan and valine were identified at the COOH
terminus of some eluted peptides. There was no character-
istic motif in the peptides preferentially associated with
B*4403.
Structural Basis of HLA-B*4402 and B*4403 Binding to a
Shared Peptide Ligand. The crystal structures of B*4402
and B*4403 were determined in complex with a shared
natural, high affinity ligand derived from HLA-DP 
(DPA*0201, residues 46–54 EEFGRAFSF) (Fig. 2 and Fig.
3 G, (M   H)    1089.6   0.2). The data collection and
refinement statistics are shown in Table II. The resolution
of the structures was 1.6 and 1.7 Å, respectively. The pep-
tide was bound in an extended conformation in both
HLA-B*4402 and B*4403, with a small bulge around Gly 4
(Fig. 4, A–D). There were 13 water-mediated hydrogen
bonds (H-bonds) and 15 direct H-bonds in the HLA–
B*4402 complex. Fewer H-bonds were observed in the
HLA–B*4403 complex (9 water mediated H-bonds and 15
direct H-bonds). The peptide also participates in three con-
served salt bridges in both complexes (Table S1 available
at http://www.jem.org/cgi/content/full/jem.20030066/
DC1). The dominant solvent-accessible residues of the
peptide ligand were Glu1, Gly4, Arg5, and Ser8, whereas
Phe3 and Phe7 are only partially solvent accessible (Fig. 4
D). In both structures, Arg5 was the most mobile residue
Figure 3. High resolution
peptide mapping of B*4402 and
B*4403 ligands reveals  5%
bound peptides are unique or pref-
erentially bound by one allotype.
(A) After an initial RP-HPLC
separation of HLA-B*4402 bound
peptides from C1R transfectants,
a second dimension RP-HPLC
separation was performed (right)
and mass spectra determined
for the selected fractions (left).
(B–G) MALDI-TOF mass
spectra of ligands from selected
fractions after a 2nd round of
RP-HPLC (A, right). Peptides
from HLA-B*4402 (positive po-
larity spectra) and HLA-B*4403
(negative polarity spectra).T
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(B factors 29–35, Å2), reflecting the greater solvent accessi-
bility of the polar head group of this residue.
Structural Basis for Selection of Shared Anchor Residues by the
B and F pockets. The antigen-binding cleft of class I HLA
molecules consists of a series of pockets designated A–F
(27, 49). In different alleles, these pockets vary in their
depth, electrostatic potential, and hydrophobicity, thus de-
termining their ligand specificity. Specificity for P2-Glu
occurs in HLA-B44, HLA-A29, and H-2Kk. However, be-
cause the structural basis for this specificity has not yet been
described, these interactions are described in some detail
here and compared with the B pockets of B*2705 (50) and
B*3501 (51, 52) that possess alternative specificities (Fig. 5).
The B pocket is formed by residues at positions 9, 24, 45,
66, 67, and 99 of the class I heavy chain; the P2-Glu inter-
acts with all these residues except for Ile66 in our structures
and makes an additional interaction (position 70). In
B*4402 and B*4403, the peptide anchor Glu2 forms a salt
bridge with Lys45, which is situated at the bottom of the B
pocket and presumably provides substantial energetic con-
Figure 4. Structures of bound DP  ligand com-
plexed to two HLA-B44 alleles, highlighting polymor-
phic amino acids and the electron density of the peptide.
The structures of the DP 46–54 (EEFGRAFSF) com-
plexed to (A) HLA-B*4402 and (B) B*4403 highlighting
the polymorphism at position 156. (C) Superposition
of the two antigen-binding clefts B*4402 (green) and
B*4403(yellow) showing the shift in the  1 helix
around residues 70–77. (D) Superposition of the two
peptide ligands (side view) highlighting the solvent-
accessible amino acids.
Figure 5. Novel structure of
the B pocket of HLA-B*4403
and B*4402 determines the se-
lection of dominant anchor resi-
dues P2 Asp/Glu. The structure
of the B pocket of HLA-B*4403
is compared with previously
reported structures for HLA-
B*2705 and HLA-B*3501. The
upper panels are ball and
stick representations of B pocket
amino acids 9, 24, 45, 66, 67, 70,
and 99 (gray) and the P2
amino acid of the ligand (green);
B*4403 (P2 Glu, left), HLA-
B*2705 (P2 Arg, middle), and
B*3501 (P2 Pro, right). The
lower panels represent electro-
static surfaces of the area bounding
the B pocket using the program
GRASP (70) and showing the
bound peptide ligand for the
structures in ball and stick format
(blue, electropositive; red, elec-
tronegative). The B pocket of
B*4402 is virtually identical to
B*4403.T
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tribution to the specificity of the B pocket (Fig. 5). Fur-
thermore, the charged P2-Glu carboxylate forms direct
H-bonds to Tyr9 and Tyr99. Additionally, there is a bur-
ied, well-ordered water molecule at the base of the pocket
that mediates H-bonds to Ser67 and Thr24 in the HLA-
B*4402/03 structures. In B*4403, this conserved water
molecule forms a H-bond to Asn70, a residue within the
 1-helix that flexes as a result of the polymorphism at posi-
tion 156. The long aliphatic moiety of Glu2 packs predom-
inantly against the aromatic ring of Tyr7 and is flanked by
Ile66, although it doesn’t interact with the latter residue.
Some of the structural framework of the B pocket is
conserved between B*4403, B*2705, and B*3501 (Fig. 5).
Thus, the B pockets of B*2705 (50) and B*4402/B*4403
are deep to accommodate the long aliphatic side chains of
arginine or glutamate. However, in contrast to B*4402 and
B*4403, the deep electronegative B pocket of B*2705 (50)
accommodates a positively charged canonical P2-Arg resi-
due involved in charge complementation with the glutamic
acid residue at position 45 of the heavy chain. In the B
pocket of HLA-B*3501, the projecting Phe67 creates a hy-
drophobic, sterically occluded pocket that preferentially ac-
commodates proline residues at P2 of bound peptide
ligands (51, 52).
The residues that surround the F pocket are very similar
in both the B*4402 and B*4403 structures, and only the
structure of B*4402 is shown in Fig. 6. The P9 anchor res-
idue phenylalanine projects into a hydrophobic F pocket,
where it stacks between the aromatic ring of Tyr123 and
the aliphatic moiety of Asn77. The main chain of this
COOH-terminal residue is tethered by H-bonds to Asn77,
Tyr84, and Thr143. In addition, the walls of the F pocket
are bound by Trp147, Tyr74, and Ile95. The large cluster
of aromatic residues within the F pocket provides a struc-
tural basis for the preference of aromatic residues at the P9
position. Asp116 forms the base of this pocket, where the
carboxylate group of Asp116 is orientated away from the F
pocket, leaving the aliphatic moiety of Asp116 to interact
with the hydrophobic Phe side chain (Table S1 and Fig. 6)
and to form a direct H-bond with Tyr74 that is lost in
B*4403.
Impact of  2 Helix Position 156Asp→Leu Polymorphism on
HLA-B*4402 and B*4403 Structures. In the structures of
both B*4402 and B*4403, the side chain of amino acid 156
was buried and, therefore, not directly accessible for TcR
interaction (Fig. 4, A and B). Superposition of the C 
backbones of peptides bound to B*4402 and B*4403 re-
vealed a root mean square deviation of 0.41 Å with a 1.0-Å
shift around Ala6 being the most significant movement be-
tween the two structures (Fig. 4 C). In HLA-B*4402,
Asp156 forms a salt bridge with Arg97 on the floor of the
cleft and participates in a number of H-bond and van der
Waals (v.d.w.) interactions. These interactions include wa-
ter-mediated H-bonds to the Arg97 guanadinium head
group and the C5 carbonyl of the peptide ligand backbone,
and an unusual direct H-bond to Asp114 (Fig. 7 A). The
H-bond between Asp156 and Asp114 orientates the
Figure 6. The F pocket of B*4402. The main chain of the peptide car-
boxy-terminal residue is tethered by H-bonds to Asn 77, Tyr 84, and Thr
143. The P9 anchor residue phenylalanine projects into a hydrophobic F
pocket where it stacks between the aromatic ring of Tyr123 and the ali-
phatic moiety of Asn 77. The walls of the pocket are bounded by Trp
147, Tyr 74, and Ile 95. Peptide residues in green, HLA heavy chain in
gray and H-bonds shown as dashed lines.
Figure 7. The structural interactions around residue 156 constrain the
antigen-binding cleft of HLA-B*4402 (156 Asp) relative to HLA-B*4403
(156 Leu) and alter the orientation of peptide side chains. The side chain
of residue 156 is shown in yellow and forms a unique H-bond with Asp
114 in B*4402 (A) that is missing in B*4403 (B), where instead Asp 114 is
reoriented to maximize its H-bond network with Arg 97, creating a
wider cavity in this region of the cleft. Peptide, green; HLA heavy chain,
gray; H-bonds, dotted lines; W, water.T
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Asp114 side chain, allowing a salt bridge to the guanadin-
ium head group of Arg97 as well as a water-mediated
H-bond to Asp116. The pairing of Asp156 and Asp114 has
not been seen in any other crystal structures of HLA class I
molecules, and is presumably stabilized by salt bridging
between both these residues and Arg97, allowing an
O–H·····H interaction between carboxylates. However,
the potential for H-bond formation between Asp156 and
Asp114 exists in several other HLA-B molecules, including
other members of the HLA-B44 family. In addition
Asp156 forms a v.d.w. interaction with Trp133 and
Leu126, as well as with Phe3 of the bound peptide ligand.
Here, the peptide Phe3–Asp156 interaction is facilitated by
the side-on orientation adopted by the Phe3 side chain.
In contrast to B*4402, the nonpolar nature of Leu156 in
B*4403 results in loss of a water-mediated H-bond to the
peptide backbone, giving rise to a significant repositioning
of the peptide between the B*4403  -helices. On the other
hand, the side chain of Leu156 in HLA-B*4403 is rotated
by  90  (Fig. 7 B), enhancing v.d.w. contacts within the
hydrophobic pocket formed by Leu126, Trp133, and
Val152. In addition, to avoid unfavorable interactions with
Leu156, the orientation of the Asp114 side chain in
B*4403 changes by  90 , simultaneously maximizing in-
teractions with Arg97 and maintaining a water-mediated
H-bond to the C5 carbonyl of the peptide backbone.
Hence, despite the loss of some H-bonds in B*4403, in-
cluding the Asp116–Tyr74 interaction, the stability of the
EEFGRAFSF peptide does not seem to be significantly im-
paired in the B*4403 complex consistent with experiments
that show little difference in the thermostability of B*4402
versus B*4403 in complex with the EEFGRAFSF peptide
(unpublished data).
However, the altered interactions between residue 156
and neighboring heavy chain residues, and the peptide
ligand, significantly change the dimensions of the Ag-bind-
ing cleft in B*4402 and B*4403 (Fig. 4, C and D). A “rigid
body shift” in the  1 helix, particularly around positions
70–77, results in a 0.6-Å displacement of the  -helices be-
tween the antigen-binding cleft of HLA-B*4402 (green)
versus B*4403 (Fig. 4 C, yellow). Amino acid residues 70–
77 lie adjacent to the central region of the peptide that has
undergone a shift of 1.0 Å in the C  backbone around
Ala6. This conformational adjustment is directly associated
with the loss of a direct H-bond between Asp116 and
Tyr74 of the B*4403 heavy chain (Fig. 7, A and B). Thus,
in the HLA-B*4402 structure the direct H-bond between
Asp116 and Tyr74 results in a narrower antigen-binding
cleft (Figs. 6 and 7 A), whereas in the B*4403 structure loss
of this interaction is associated with distortion and relative
“breathing” of the binding cleft (Fig. 7 B). Instead of mak-
ing a direct H-bond with Asp116, Tyr74 participates in a
water-mediated H-bond with this residue in HLA-B*4403;
this is attributable to changes in the peptide orientation, re-
sulting from the substitution at amino acid 156. Conse-
quently, the slightly larger cavity of the HLA-B*4403 cleft
is occupied by an acetate ion in this structure, reflecting
potentially greater accommodation of peptide side chains
by the B*4403 allotype compared with B*4402 (Fig. 7 B).
Any thermodynamic penalty for “breathing” of the B*4403
cleft may not be apparent with some ligands because of
compensatory peptide interactions arising from the altered
cleft structure, as appears to be the case for B*4403 binding
of the EEFGRAFSF peptide.
Discussion
The impact of point mutations and other micropolymor-
phisms on the structure and function of class I molecules has
been studied extensively by in vitro mutagenesis (53, 54)
and through exploitation of the experimentally derived Kb
mutant system (3, 44, 47, 48). These systems have been
enormously important for unraveling key details of struc-
ture–function relationships in MHC molecules. However,
it is equally important to study the structural and functional
consequences of naturally selected microvariation in HLA
allotypes found in outbred human populations. To this end,
we have determined the structural and functional properties
of two closely related, naturally occurring human class I al-
leles, HLA-B*4402 and B*4403. These were studied be-
cause of their evolutionary success as common alleles in di-
verse human populations, notwithstanding their marked
structural similarity and shared peptide binding motif.
Structural differences in B*4402 and B*4403 are distin-
guishable by many T cells and these allotypes provoke
strong, mutual allogeneic T cell responses in vitro. Indeed,
up to 25% of CD8  T cells are specifically alloreactive in
extended MLRs between B*4402/B*4403 mismatched in-
dividuals. These observations indicate that B*4402 and
B*4403 molecules select both shared and unique T cells
during thymic development.
The structures of B*4402 and B*4403 show that amino
acid 156 is neither solvent accessible, nor directly involved
in forming major specificity pockets. Nonetheless, the
156Asp→Leu polymorphism is a nonconservative substitu-
tion and markedly alters the characteristics of the P3 speci-
ficity (E pocket) as well as the secondary effects of the anti-
gen-binding cleft. Hence, the 156Asp→Leu substitution
alters the repertoire of peptide ligands bound by both mol-
ecules and directly alters the conformation of the antigen-
binding cleft. Subtle differences were observed in preferred
residues at minor anchor sites in B*4403 versus HLA-
B*4402, however, these differences may be more apparent
than real. For instance, a Trp can be modeled at P  in
B*4402 and B*4403 (unpublished data) and a tryptophan is
found at P  in the EEVDLSKDIQHW peptide eluted
from both B*4402 and 4403 (Table I). Thus, any prefer-
ence for Trp at P  in B*4402 is probably quantitative (sta-
tistical) or context-dependent.
The peptide repertoire of HLA-B*4402 and B*4403
showed   95% overlap but most of the unique peptides
were associated with B*4403. These differences in peptide
selection can be partly understood by an examination of the
two structures. Comparison of the antigen-binding cleft of
HLA-B*4402 and B*4403 revealed a relative narrowing of
the B*4402 cleft between the  -helices, particularly aroundT
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amino acids 70–77. This distortion of the cleft shape appears
to be the result of both indirect and ligand-mediated con-
formational changes associated with the 156Asp→Leu poly-
morphism. The Asp114–Asp156 interaction in B*4402 is
unusual, and being constrained, appears to limit the type of
residue that can sit in the P3, and/or the P7 pocket. A large
network of polar interactions at position 156 dissipates this
unfavorable interaction and draws the helix 1 closer to the
peptide, thereby sterically constraining the makeup of po-
tential bound peptides in B*4402. Thus, the relatively re-
stricted range of ligands recovered from B*4402 compared
with B*4403 probably results from this structural constraint
that limits the size of side chains that can be accommodated
in the narrowed region. In contrast, the 156Asp→Leu sub-
stitution in B*4403 results in a loss of this bonding network,
allowing the helices to breathe in this region. This breathing
of the cleft is further reflected by the presence of an acetate
moiety in the extra space around amino acids 70–77 in the
B*4403/EEFGRAFSF complex. Breathing, or opening of
the binding cleft, is also observed in the structures of HLA-
DQ8 (55) and I-Ag7 (56) when these are compared with
other class II molecules.
The orientation of side chains in the EEFGRAFSF pep-
tide bound by HLA-B*4402 and B*4403 was also altered
by the 156Asp→Leu polymorphism. Structural adjustments
within identical ligands bound by related MHC allotypes
can be sufficient to induce T cell alloreactivity (24). How-
ever, altered heavy chain conformation (57) and binding of
unique ligands (58) can also contribute to T cell alloreactiv-
ity. Thus, T cell discrimination of B*4402 and B*4403, ei-
ther during positive selection of the T cell repertoire, or
during B*4402 anti-B*4403 alloreactions, could involve
any one, or all of the modes of recognition discussed here.
Ironically, the structural similarity between B*4402 and
B*4403 is likely to engender strong reciprocal T cell al-
loreactivity due to thymic selection of a large repertoire of
T cells with intrinsic “B44”-reactivity biased toward these
allotypes. Hence, the number of T cells that can distin-
guish subtle structural differences in B*4402 and B*4403 is
likely to be very significant. Thus, the magnitude of the al-
loresponse is paradoxically as great, or even greater, than
observed across more disparate HLA allelic differences
(19–21)
The subtle differences in peptide repertoire between
B*4402 and B*4403 contrast with the differences observed
between many HLA class I allotypes, especially where sub-
stitutions occur in the dominant anchor residues located
within the B and F pockets (59–61). For instance, HLA-
B*2705 and B*2709 differ at position 116 (Asp→His) at the
base of the F pocket (62, 63), resulting in peptide reper-
toires that overlap by  79 and  88%, respectively (64),
and producing mutual alloreactivity (62, 65).
However, natural class I polymorphism outside the P2
and P  peptide anchor sites appears to modulate peptide
repertoire in a much more subtle, often imperceptible
manner, as reported for subtypes of HLA-B7, B17 and B15
(66), B5 and B22 (67), and B27 (65–69). Thus, our find-
ings in relation to B*4402 and B*4403 are likely to be of
general relevance in understanding the impact of microva-
riation in HLA class I genes. For instance, among all
known HLA class I molecules, there are five different
amino acids observed at position 156 (Asp, Leu, Arg, Gln,
and Trp). Dimorphism at this residue is found in virtually
all the common class I subtypes, suggesting that this posi-
tion exerts a strong influence on the structure and function
of other class I allotypes as well as B44 (25).
The functional basis underlying the retention of the
B*4402 and B*4403 alleles in diverse human populations
presumably rests with their independent selective advantage
in immunity. Selection could be related to differential
ligand selection by B*4402 and B*4403 (1); or, alterna-
tively, may reflect differences in either thymic positive se-
lection of T cells (44) or clonal diversification of the pe-
ripheral immune response (3). In addition, selection could
be influenced by other elements of conserved HLA-B44
haplotypes, although these are not well-preserved in all
populations, making this explanation less likely.
We conclude that the relatively small changes in peptide
repertoire and MHC–peptide conformation between nat-
urally occurring HLA polymorphisms can be sufficient to
maintain selection of these alleles in diverse human popu-
lations. These micropolymorphisms are potentially capable
of enhancing protective immunity by expanding ligand se-
lection but are also likely to diversify T cell repertoire dur-
ing thymic positive selection and at the time of the im-
mune response.
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